Last 15,000 KRW
Change Today -2,600.00 / -14.77%
Volume 397.5K
008930 On Other Exchanges
Symbol
Exchange
Korea SE
As of 2:24 AM 10/21/14 All times are local (Market data is delayed by at least 15 minutes).

hanmi science co ltd (008930) Snapshot

Open
17,600
Previous Close
17,600
Day High
17,600
Day Low
15,000
52 Week High
07/18/14 - 20,250
52 Week Low
12/23/13 - 11,619
Market Cap
818.3B
Average Volume 10 Days
119.6K
EPS TTM
182.00
Shares Outstanding
54.6M
EX-Date
12/28/12
P/E TM
82.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for HANMI SCIENCE CO LTD (008930)

Related News

No related news articles were found.

hanmi science co ltd (008930) Related Businessweek News

No Related Businessweek News Found

hanmi science co ltd (008930) Details

Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. The company offers prescription drugs in the areas of antidepressant, NSAIDs, neuropathic pain, obesity, epilepsy, lactobacillus intestinal supplement, oral care, hair growth, anti-inflammatory, schizophrenia, CNS, cough, smoking cessation aid, diabetes, total parenteral nutrition, osteoporosis, antiemetic, vaginal contraceptive, expectorants, ophthalmic, immunosuppressant, prostatism, urinogenital, cancer, antitussives, vitamins and nutritional supplements, constipation, dermatology, Parkinson's Disease, hepatitis, antibiotics, gastrointestinal, cardiovascular, and muscle relaxation. It also offers OTC drugs, including NSAID, oral care, myalgia, sinus cold, antitussives, ophthalmic, gum disease prevention, antihistamines, and hypnotics drugs, as well as calcium supplements, iron supplements, vitamins, and nutritional supplements. In addition, the company offers active pharmaceutical ingredients (APIs), including sterile cephalosporin, oral cephalosporin, and general APIs. It offers its products in various forms, such as tablets, capsules, and oral suspensions. The company was formerly known as Hanmi Holdings Co., Ltd. and changed its name to Hanmi Science Co., Ltd. in March, 2012. Hanmi Science Co., Ltd. was founded in 1973 and is headquartered in Seoul, South Korea.

Founded in 1973

hanmi science co ltd (008930) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

hanmi science co ltd (008930) Key Developments

Hanmi Science Co., Ltd., Annual General Meeting, Mar 14, 2014

Hanmi Science Co., Ltd., Annual General Meeting, Mar 14, 2014., at 09:30 Korea Standard Time. Location: wiryeseong 14 , Songpa-gu. Agenda: To consider article 41 group financial statements including the statement of retained earnings; to consider approval of the appointment of audit; to consider officers of the regulatory changes in severance payments; to consider approval of director remuneration; and to consider approval of the remuneration thanks.

Cell>Point L.L.C. and Hyun Imc Co. Ltd Expand License in South Korea to Include Hanmi Science Co., Ltd. for Cancer and Heart Disease Imaging

Cell>Point L.L.C. announced that it entered into a license agreement on December 17, 2012 with Hanmi Science Co., Ltd. The license agreement also includes Hyun Imc Co. Ltd. as a party (who Cell>Point previously entered into a license with in February 2012 and subsequently amended and restated the license agreement with HYUN IMC on December 4, 2012). The license agreement with Hanmi covers the kit manufacture, marketing and distribution of Cell>Point's cancer and cardiology imaging product based on its Ethylenedicysteine-Glucosamine (EC-G) technology platform. The initial product will be technetium-99m labeled EC-G ((99m) Tc-EC-G) for SPECT and SPECT/CT imaging. Downstream, the license agreement will cover gallium-68 labeled EC-G ((68) Ga-EC-G) for PET/CT imaging. In addition, Hanmi has been granted a Right of First Refusal regarding Cell>Point's cold metallic therapeutic products Platinum-EC-G and (187) Rhenium-EC-G, and two imaging products, (99m) Tc-EC-Annexin V to image tumor cell apoptosis, and (99m) Tc-EC-Metronidazole to image tumor cell hypoxia. Cell>Point receives upfront payments, milestone progress payments, and a royalty on commercial sales.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
008930:KS 15,000.00 KRW -2,600.00

008930 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 008930.
View Industry Companies
 

Industry Analysis

008930

Industry Average

Valuation 008930 Industry Range
Price/Earnings 34.8x
Price/Sales 2.1x
Price/Book 1.8x
Price/Cash Flow 34.2x
TEV/Sales 1.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HANMI SCIENCE CO LTD, please visit www.hanmi.co.kr. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.